These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 36858198)

  • 1. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
    McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
    Ott HM; Graves AP; Pappalardi MB; Huddleston M; Halsey WS; Hughes AM; Groy A; Dul E; Jiang Y; Bai Y; Annan R; Verma SK; Knight SD; Kruger RG; Dhanak D; Schwartz B; Tummino PJ; Creasy CL; McCabe MT
    Mol Cancer Ther; 2014 Dec; 13(12):3062-73. PubMed ID: 25253781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
    Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
    Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
    Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
    Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
    Wu H; Zeng H; Dong A; Li F; He H; Senisterra G; Seitova A; Duan S; Brown PJ; Vedadi M; Arrowsmith CH; Schapira M
    PLoS One; 2013; 8(12):e83737. PubMed ID: 24367611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of histone methylation by automethylation of PRC2.
    Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
    Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation.
    Sahasrabuddhe AA; Chen X; Chung F; Velusamy T; Lim MS; Elenitoba-Johnson KS
    Oncogene; 2015 Jan; 34(4):445-54. PubMed ID: 24469040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
    Xu B; Konze KD; Jin J; Wang GG
    Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of automethylated PRC2 by dimerization on chromatin.
    Sauer PV; Pavlenko E; Cookis T; Zirden LC; Renn J; Singhal A; Hunold P; Hoehne-Wiechmann MN; van Ray O; Kaschani F; Kaiser M; Hänsel-Hertsch R; Sanbonmatsu KY; Nogales E; Poepsel S
    Mol Cell; 2024 Oct; 84(20):3885-3898.e8. PubMed ID: 39303719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.
    Sneeringer CJ; Scott MP; Kuntz KW; Knutson SK; Pollock RM; Richon VM; Copeland RA
    Proc Natl Acad Sci U S A; 2010 Dec; 107(49):20980-5. PubMed ID: 21078963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
    Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
    Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
    Mu W; Starmer J; Yee D; Magnuson T
    Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
    Dockerill M; Gregson C; O' Donovan DH
    Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
    Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
    Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycomb Repressive Complex 2 in Oncology.
    Guo Y; Yu Y; Wang GG
    Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
    Hwang IJ; Park J; Seo SB
    Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
    Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
    Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.